ATC code L01
Abemaciclib (data page)
Aclarubicin
Adagrasib
Adenosine deaminase inhibitor
Aflibercept
Alitretinoin
Alkyl sulfonate
Alkylating antineoplastic agent
Alpelisib
Altretamine
Alvocidib
American Society of Health-System Pharmacists
Aminolevulinic acid
Aminopterin
Amrubicin
Amsacrine
Anagrelide
Anatomical Therapeutic Chemical Classification System
Anemia
Anthracycline
Anthraquinone
Antifolate
Antimetabolite
Antineoplastic
Apoptosis
Arsenic trioxide
Asparaginase
Asparagine
Atrasentan
Axicabtagene ciloleucel
Azacitidine
Aziridine
Belinostat
Belotecan
Belzutifan
Bendamustine
Bexarotene
Bioavailability
Biological half-life
Bisantrene
Bleomycin
Blood plasma
Bortezomib
Brain tumor
Breakthrough therapy
Breast cancer
Brexucabtagene autoleucel
Buchwaldâ€“Hartwig amination
Busulfan
CAS Registry Number
CDK4
CDK6
CDK inhibitor
CYP3A4
Cabazitaxel
Camptotheca
Camptothecin
Capecitabine
Carboplatin
Carboquone
Carfilzomib
Carmofur
Carmustine
Celecoxib
Cell-cycle nonspecific antineoplastic agents
Cell cycle
ChEMBL
ChemSpider
Chemical formula
Chemotherapy
Chlorambucil
Chlormethine
Cholangiocarcinoma
Ciltacabtagene autoleucel
Cisplatin
Cladribine
Clinical trial
Clofarabine
CompTox Chemicals Dashboard
Copanlisib
Cositecan
Crisnatol
Crosslinking of DNA
Cyclin-dependent kinase
Cyclin-dependent kinase 4
Cyclin-dependent kinase 6
Cyclophosphamide
Cytarabine
DNA polymerase inhibitor
DNA replication
Dacarbazine
Dactinomycin
DailyMed
Daunorubicin
Daunorubicin/cytarabine
Decitabine
Demecolcine
Denileukin diftitox
Deoxyribonucleotide
Dicycloplatin
Dihydrofolate reductase inhibitor
Docetaxel
Doi (identifier)
Doxifluridine
Doxorubicin
DrugBank
Drug development
Drug nomenclature
Drugs.com
Duvelisib
ECHA InfoCard
Efaproxiral
Eflornithine
Elesclomol
Eli Lilly and Company
Elimination half-life
Elsamitrucin
Enasidenib
Endothelin receptor antagonist
Entinostat
Enzyme inhibitor
Epacadostat
Epirubicin
Epothilone
Eribulin
Estramustine phosphate
Etirinotecan pegol
Etoglucid
Etoposide
Eva Y.-H. P. Lee
Exatecan
Excretion
Farnesyltransferase inhibitor
Fatigue (medical)
First gap phase
Floxuridine
Fludarabine
Fluorouracil
Food and Drug Administration
Fotemustine
Fulvestrant
Fuzuloparib
Gemcitabine
Gimatecan
Glasdegib
Halogenation
Head and neck cancer
Health Canada
Histone deacetylase inhibitor
Human epidermal growth factor receptor 2
Hydrazine
Hydroxycarbamide
Hydroxyl
Hypomethylating agent
IMP dehydrogenase
IUPAC nomenclature of chemistry
Idarubicin
Idecabtagene vicleucel
Idelalisib
Ifosfamide
Imetelstat
Inavolisib
Intercalation (biochemistry)
International Chemical Identifier
Irinotecan
Isocitrate dehydrogenase
Ivosidenib
Ixabepilone
Ixazomib
JSmol
KEGG
Kaposi's sarcoma
Ketoconazole
Larotaxel
Leuckart reaction
Leukopenia
Lifileucel
Lipoxygenase inhibitor
Lisocabtagene maraleucel
List of withdrawn drugs
Lomustine
Lonidamine
Losoxantrone
Lucanthone
Lurbinectedin
Lurtotecan
M phase
Mannosulfan
Mantle cell lymphoma
Masoprocol
Medication
Melphalan
Melphalan flufenamide
Menogaril
Mercaptopurine
Metabolite
Methotrexate
Methyl aminolevulinate
Microtubule
Mitobronitol
Mitoguazone
Mitomycins
Mitotane
Mitotic inhibitor
Mitoxantrone
Mitozolomide
Molar mass
Nadofaragene firadenovec
Nausea
Navitoclax
Nedaplatin
Nelarabine
Neurofibromatosis
Neutropenia
Nimustine
Niraparib
Niraparib/abiraterone acetate
Nitrogen mustard
Nitrosourea
Obecabtagene autoleucel
Oblimersen
Olaparib
Olutasidenib
Omacetaxine mepesuccinate
Oprozomib
Oral administration
Ortataxel
Oxaliplatin
Oxidative
PARP inhibitor
PMC (identifier)
PMID (identifier)
Paclitaxel
Padeliporfin
Palbociclib
Panobinostat
Pegaspargase
Pemetrexed
Pentostatin
Pharmacokinetics
Phases of clinical research
Phosphodiesterase inhibitor
Phosphoinositide 3-kinase inhibitor
Phosphorylation
Photodynamic therapy
Photosensitizer
Pipobroman
Pirarubicin
Pixantrone
Placebo
Plasma protein
Plasma protein binding
Platinum-based antineoplastic
Plicamycin
Plitidepsin
Podophyllum peltatum
Porfimer sodium
Porphyrin
Pralatrexate
Prednimustine
Prescription drug
Procarbazine
Progression-free survival
Proteasome inhibitor
Protein Data Bank
Protein kinase inhibitor
PubChem
Purine analogue
Pyrimidine analogue
Rabacfosadine
Raltitrexed
Ranimustine
Receptor antagonist
Reductive amination
Regulation of therapeutic goods
Renal cell carcinoma
Retinoblastoma protein
Retinoid
Retinoid X receptor
Ribociclib
Ribonucleotide reductase inhibitor
Rifampicin
Romidepsin
Route of administration
Rubitecan
Rucaparib
S2CID (identifier)
S phase
Satraplatin
Seliciclib
Selinexor
Semustine
Sex steroid
Silatecan
Simplified molecular-input line-entry system
Sitimagene ceradenovec
Sotorasib
Spindle poison
Standard for the Uniform Scheduling of Medicines and Poisons
Streptomyces
Streptozotocin
Suzuki coupling
Synthesis phase
Tabelecleucel
Tagraxofusp
Talaporfin
Talimogene laherparepvec
Taxane
Tazemetostat
Tebentafusp
Tegafur
Tegafur/gimeracil/oteracil
Temoporfin
Temozolomide
Teniposide
Tesetaxel
Testolactone
Thiopurine
Thiotepa
Thrombocytopenia
Thymidylate synthase inhibitor
Tiazofurin
Tiazofurine
Tigilanol tiglate
Tioguanine
Tipifarnib
Tisagenlecleucel
Topoisomerase inhibitor
Topotecan
Trabectedin
Treosulfan
Tretinoin
Triazene
Triaziquone
Triethylenemelamine
Trofosfamide
Type II topoisomerase
Type I topoisomerase
Umbralisib
Unique Ingredient Identifier
Uramustine
Valrubicin
Veliparib
Venetoclax
Verdinexor
Verteporfin
Vinblastine
Vinca alkaloid
Vincristine
Vindesine
Vinflunine
Vinorelbine
Vorasidenib
Vorinostat
Vosaroxin
WHO Model List of Essential Medicines
Zorubicin